Compare CZNC & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CZNC | CCCC |
|---|---|---|
| Founded | 1864 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 377.5M | 404.7M |
| IPO Year | 2009 | 2020 |
| Metric | CZNC | CCCC |
|---|---|---|
| Price | $21.88 | $3.87 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $23.50 | $12.20 |
| AVG Volume (30 Days) | 37.2K | ★ 2.9M |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.87% | N/A |
| EPS Growth | 7.64 | ★ 16.45 |
| EPS | ★ 0.02 | N/A |
| Revenue | N/A | ★ $35,947,000.00 |
| Revenue This Year | $3.11 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1,096.25 | ★ N/A |
| Revenue Growth | N/A | ★ 1.02 |
| 52 Week Low | $18.16 | $1.36 |
| 52 Week High | $24.12 | $4.60 |
| Indicator | CZNC | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 58.38 | 54.33 |
| Support Level | $20.02 | $2.13 |
| Resistance Level | $22.48 | $3.89 |
| Average True Range (ATR) | 0.41 | 0.38 |
| MACD | 0.19 | -0.05 |
| Stochastic Oscillator | 90.00 | 31.95 |
Citizens & Northern Corp is a community bank operating through its subsidiaries. It provides banking services, including deposit and loan products for personal and commercial customers. The bank also maintains a trust division that provides a wide range of financial services, such as 401(k) plans, retirement planning, estate planning, estate settlements and asset management.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.